Compound tirzepatide: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtag stack, @latricia_nicole is almost certainly sharing a personal update on compounded tirzepatide, the ingredient found in brand-name Mounjaro and Zepbound. These videos follow a recognizable pattern: the creator discusses switching from brand-name to compounded versions, reports on weight loss progress, injection experiences, or supply chain wins. The "UPDATE" framing suggests she's been on compounded tirzepatide for some time and is reporting outcomes or dosing changes. With 58K views, this is meaningful reach. Viewers are likely walking away with impressions about compounded tirzepatide's effectiveness and safety that may or may not reflect how the clinical and regulatory picture actually looks right now. That gap is exactly what needs examining.

What does the science actually show?

The clinical evidence for tirzepatide itself is genuinely strong. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15 mg weekly tirzepatide lost a mean of 20.9% of body weight over 72 weeks, compared to 3.1% for placebo. That's a real number, not a rounding error. SURMOUNT-2 extended findings to adults with obesity and type 2 diabetes, with mean weight loss of 15.7% at 15 mg. The drug works by acting on both GIP and GLP-1 receptors, giving it a distinct mechanism from semaglutide. What the clinical trials do not tell us is how compounded versions, which are manufactured by 503A and 503B pharmacies and are not FDA-approved, compare in bioavailability, sterility, or potency to the brand-name product.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the implicit assumption that compounded tirzepatide is interchangeable with Zepbound or Mounjaro. It is not, legally or clinically. The FDA has never reviewed compounded tirzepatide formulations for safety or efficacy. In February 2025, the FDA declared the tirzepatide shortage resolved, which triggered legal restrictions on most compounding, a fact many TikTok creators either don't know or don't mention. Compounders can still serve patients with documented allergies to excipients in brand-name products, but blanket compounding for cost reasons is now in a legally contested gray zone. Personal results shared in these videos also suffer from obvious selection bias: people losing weight post and celebrate; people who stall or experience adverse effects typically don't. Nausea, vomiting, and gastrointestinal side effects affected roughly 30-45% of SURMOUNT-1 participants and that context rarely makes it into the caption.

What should you actually know?

If you're considering compounded tirzepatide, the regulatory situation is the first thing to understand, not the last. The FDA's position as of early 2025 is that tirzepatide is no longer on the shortage list, which means most compounding is either prohibited or under active legal challenge. Some 503B outsourcing facilities have sued the FDA over this designation. The outcome of those cases matters to whether what you're ordering is even legal to ship. Beyond legality, quality control varies significantly between compounding pharmacies. Unlike FDA-approved drugs, compounded products don't go through standardized batch testing for potency or sterility at a federal level. If a creator's results look dramatically better or worse than SURMOUNT trial averages, formulation differences are a plausible explanation. Always verify your pharmacy's 503A or 503B registration status and talk to a licensed clinician before starting any compounded GLP-1 medication.